Physician profile
John Fox
NPI 1992786305
$1,351.15
in general payments reported to CMS, 2019-2025
19 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $14.84 · 2021: $209 · 2022: $191 · 2023: $120 · 2024: $336 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $606.46 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $173.48 | 2021-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Pfizer INC. | $92.47 | 2019-2025 | |
| Amgen INC. | $80.46 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $53.29 | 2024-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.98 | 2022-2023 | Spiriva Respimat, Stiolto Respimat |
| Phathom Pharmaceuticals, INC. | $43.30 | 2025 | Voquezna |
| Genzyme Corporation | $39.74 | 2024 | |
| Medtronic, INC. | $28.62 | 2021 | |
| Lilly USA, LLC | $27.31 | 2019-2022 | |
| Novo Nordisk INC | $26.90 | 2019 | |
| Melinta Therapeutics, LLC | $24.90 | 2021 | |
| Insulet Corporation | $21.60 | 2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.13 | 2024 | Caplyta |
| Actelion Pharmaceuticals US, INC. | $15.48 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15.04 | 2024 | Gattex |
| Tonix Medicines, INC. | $14.11 | 2025 | Tonmya |
| Novartis Pharmaceuticals Corporation | $13.89 | 2025 | |
| Glaxosmithkline, LLC. | $12.99 | 2023 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.